8 results about "Precancerous Cells" patented technology

Aspects of the present disclosure are directed to at least methods and compositions for diagnosis and / or treatment of diseases associated with aberrant levels of m5C RNA, including but not limited chromatin associate RNA (caRNA). The disease may comprise cancer and / or pre-cancerous cells. The disease may be associated with mutations in a TET2 pathway, including but not limited to mutations in TET2, IDH1, IDH2, and / or ASXL1 encoding genes. Treatment of a disease may comprises administration of one or more inhibitors of MBD6, TET2, and / or NSUN2. Also provided herein are methods of treatment of a disease in an individual comprising administering one or more inhibitors of MBD6, TET2, and / or NSUN2 to the individual determined to have aberrant m5C RNA modifications.

A method and apparatus for the targeted delivery of chemotherapy to a surgical cavity, consisting of a triggered nanoparticle encapsulating a therapeutic agent and an energy delivery device that applied trigger energy to the surgical cavity. Following surgical removal of a cancerous tumor, the nanoparticle is administered, and the energy delivery device applies trigger energy to the surgical cavity and proximal tissue. The goal is the delivery of a therapeutic drug dose to cancerous and precancerous cells remaining after surgery, to prevent local tumor recurrence.

A method and apparatus for the targeted delivery- of chemotherapy to a surgical cavity, including a triggered nanoparticle encapsulating a therapeutic agent and an energy delivery device that applied trigger energy- to the surgical cavity-. Following surgical removal of a cancerous tumor, the nanoparticle is administered, and the energy- delivery- device is configured to apply trigger energy to the surgical cavity and proximal tissue. Delivery of a therapeutic drug dose to cancerous and precancerous cells remaining after surgery may prevent local tumor recurrence.

A method for sample preparation and / or DNA amplification from urine, saliva and / or mouthwash samples is disclosed. The method involves providing a sample preparation system comprising a filter and providing a urine, saliva and / or mouthwash sample, then filtering at least a portion of the sample through the filter, thereby retaining bacteria, fungi, viruses protists and / or cancerous or precancerous cells in the filter. Subsequently a lysis reagent is applied to the filter. Finally, the DNA found in the lysate is amplified.

Provided herein are compositions, systems, kits, and methods for topically applying a composition to a body area of ​​interest adjacent to and having precancerous and / or cancerous cells (e.g., skin cancer cells), wherein the composition comprises N-phosphonacetyl-L-aspartic acid (PALA) (also known as sparphosic acid) and water, and optionally further comprising at least one nonionic surfactant.

Provided herein are compositions, systems, kits, and methods for topically applying a composition to a subject having pre-cancerous cells and / or cancerous cells (e.g., skin cancer cells) and / or a body region adjacent potential pre-cancerous cells and / or cancerous cells, wherein the composition comprises N-phosphonoacetyl-L-aspartic acid (PALA) (also known as phosphine aspartic acid) and water, and optionally further comprises at least one non-ionic surfactant.

Synergistic combinations of compounds that inhibit the growth of cancerous and precancer cells, including cervical cancerous or precancerous cells and / or colon cancerous or precancerous cells.

Methods of identifying deleterious mutations and driver mutations comprising, identifying a mutation that disrupts or creates a splice donor or splice acceptor site and calculating a functional divergence score for the mutation wherein a score beyond a predetermined threshold indicates the mutation is a deleterious mutation are provided. Methods of evaluating or detecting cancer or a precancerous cell comprising identifying in genomic DNA mutations that disrupt or create a splice donor site or a splice acceptor site are also provided.